8/13/2019 OSA Updates
1/64
Dr R. MuventhiranInstitut Perubatan RespiratoriKuala Lumpur
8/13/2019 OSA Updates
2/64
! Is part of a group characterized by disorderedrespiration during sleep known as sleep relatedbreathing disorders:
Sleep relatedhypoventilation and
hypoxemic syndrome s
ObstructiveSleep Apneas
SRBD
Central SleepApnea and
PeriodicBreathing
8/13/2019 OSA Updates
3/64
! OSAHS represents one end of a spectrum withnormal quiet regular breathing at one end,moving through worsening levels of snoring,to increased upper airways resistance, and tohypopnoeas and apnoeas at the other end
8/13/2019 OSA Updates
4/64
WAKE
DEFICIENT UAANATOMY
SLEEP
Adiposesoft tissuedeposition
Compensatedby high
pharyngealactivity
CompromisedcraniofacialAirway
edema
Decreasedlung
volumes
Sleep onset1. UA musc tone2. Lung volume3. Central resp
drive
UA closure/apnea
CO2/ O2
Increased centralrespiratory and UA
muscle drive
Hypoxic and
hypercapnicresponsivenessImportance of
controller/plantgain
VENTILATORYCONTROL
INSTABILITY
If level of reachesarousal threshold
Arousal
1.
UA musc tone2. Lung volume
Decreased centralrespiratory and UA
muscle drive
UAopening
Hyperventilation/ventilatory overshoot
CO2/ O2
Hypoxic and hypercapnicresponsiveness
8/13/2019 OSA Updates
5/64
Obesity (BMI> 30) Congestive heart Failure AF
Refractory HPT Type 2 DM Nocturnal arrhythmias
CVA Pulmonary hypertension
High-risk driving population Pre-operative for bariatric surgery
8/13/2019 OSA Updates
6/64
! None of the questionnaires are sensitive or specific tosubstitute for objective assessment by a sleep study
BerlinQuestionnare
To predict whetherpt high risk or lowrisk for having OSA
identified high risk based on AHI>5 sensitivity:0.86 specificity : 0.77
STOP BANGquestionnaire
Screening tool forpreoperativeevaluation to detectOSA
Sensitivity : 84% ( AHI>5), 92%(AHI>15) and 100% (AHI>30)
8/13/2019 OSA Updates
7/64
OSA PHYSICAL EXAMINATIONINCREASED BMI
PRESENCE OF NASAL OBSTRUCTION
INCREASED MALLAMPATI OR MODIFIED MALLAMPATI SCORE
HIGH ARCHED PALATE (NARROW AIRWAY)
RETROGNATHIA
INCREASED NECK CIRCUMFERENCE ( MEN>17 INC, WOMEN>16 INC)
EVIDENCE OF RIGHT HEART FAILURE ( JVD,PEDAL EDEMA)
8/13/2019 OSA Updates
8/64
INTERNATIONAL CLASSIFICATION OF SLEEP DISORDERS, 2 ND EDITION , CRITERIA FOR OSA
A At least one of the following i) Complaints of unintentional sleep episodes during
wakefulness ,daytime sleepiness , un-refreshing sleep,fatigue or insomnia Ii) awakenings with breath holding, gasping or choking Iii) bed partner reports loud snoring and/or breathinginteruptions during sleep
B PSG shows the following i) scoreable respiratory events (A+H+RERA) /hr > 5/hr ii) Evidence of respiratory effort during all or a portion ofeach respiratory event
C PSG shows the following i) scoreable respiartory events ( A+H+RERA)/hr >15/hr
ii) Evidence of respiratory effort during all or a portion ofeach respiratory event
D The disorder is not better explained by another currentsleep disorder, medical or neurologic disorder, medicationuse or substance use disorder
DIAGNOSTIC CRITERIA= A+B+D OR C+D
8/13/2019 OSA Updates
9/64
! Gold standard: In laboratory polysomnogramA standard PSG typically consists of! EEG! segmental (+/-) tibialis electromyogram! electro-oculogram! respiratory airflow (usually measured by oronasal
flow monitors)! thoraco-abdominal movement! oxygen saturation tracings (oximetry).! Electrocardiogram (ECG) and body position are also
frequently monitored, as is snoring
8/13/2019 OSA Updates
10/64
CONSIDERATION WHOM TOTREAT?
SYMPTOMATIC ASYMPTOMATIC ASYMPTOMATIC
AHI No significantco-morbidities
Significant co-morbidities
MILD Treat Observation or
conservativetreatment
? Treat*
MODERATE Treat Treat Treat
SEVERE Treat Treat Treat
Conservative treatment: weight loss ,side sleep position,treat nasal
congestion ,avoid alcoholFor asymptomatic pts with mild OSA and significant medical co-morbidities,treatment decisions should be individualised based on patients motivationto undergo treatment
8/13/2019 OSA Updates
11/64
AMERICAN ACADEMY OF SLEEP MEDICINE PRACTICE PARAMETERRECOMMENDATION FOR MEDICAL TREATMENT OF OSA
WEIGHTREDUCTION
successful dietary weight loss may improve the AHI inobese OSA pts (guidelines)
dietary weight loss should be combined with primarytreatment of OSA (Option)
Bariatric surgery may be adjunctive in treatment of OSA inobese pts (Option)
POSITIONALTHERAPIES
Positional therapy ,consisting of a method that keeps thepatient in a non-supine position, is an effective secondarytherapy or can be supplement to primary therapies for OSAin pts who have a low AHI in the non-supine versus thesupine
OXYGENSUPPLEMENTATION
Oxygen supplementation is not recommended as a primarytreatment for OSA ( Option)
NASALCORTICOSTEROIDS
Topical nasal cortiocsteroids may improve the AHI in ptswith OSA and concurrent rhinitis and ,thus may be usefuladjunct to primary therapies for OSA ( Guideline)
8/13/2019 OSA Updates
12/64
TREATMENT ALTERNATIVES FOR OSA ADULTS)
SNORING MILD
Primary Treat nasal congestion
Lateral positioning Avoid alcohol
If symptomatic and keen:
PAP
Secondary if medical tx does notimprove congestion ! OA orsurgery ( but snoringimprovement is variable) LAUP Radio-frequencypalatoplasty UPPP Pillar procedure- may reduce
snoring but not AHI
If symp but not keen for PAP OA or Upper airway surgeryDepends on pt preference andfinancial
Adjunctive Weight loss weight loss lateral positioning
LAUP laser assisted uvulopalatplasty
8/13/2019 OSA Updates
13/64
TREATMENT ALTERNATIVES FOR OSA ADULTS)
MODERATE SEVERE
Primary Treatment of choice:
PAP
PAP
Secondary If not acceptable OA (50% effective*) Upper airwaysurgery( 30% effective*)* Defined as tx AHI
8/13/2019 OSA Updates
14/64
8/13/2019 OSA Updates
15/64
TYPE 1: ATTENDED PSG TYPE 2: UNATTENDED PSG
Measures(channels)
Minimum of sevenchannels including ECG,EEG, EOG, chin EMG,airflow, respiratoryeffort, oxygensaturation
Minimum of sevenchannels including EEG,EOG, chin EMG, heart rateor ECG, airflow, respiratoryeffort, oxygen saturation
Body position Documented orobjectively measured
Possible
Leg movement EMG or motion sensordesirable but optional
Optional
Personnelinterventions
Possible No
8/13/2019 OSA Updates
16/64
TYPE 3: MODIFIEDPORTABLE SLEEP APNEATESTING
TYPE 4: CONTINUOUSSINGLE OR DUALBIOPARAMETERRECORDING
Measures
(channels)
Minimum of four, including
ventilation (at least twochannels of respiratorymovement or respiratorymovement and airflow),heart rate or ECG, andoxygen saturation
Minimum of one
oxygen saturation,flow, or chestmovement
Body position Possible No
Leg movement Optional No
Personnelinterventions
No No
8/13/2019 OSA Updates
17/64
Indications for Use of Unattended Portable Monitoring
PM must be combined with a comprehensive sleep evaluation.
Patient has a high pretest probability of moderate to severe OSA.
No co-morbid medical conditions that may degrade PM accuracy Severe pulmonary disease. Neuromuscular disease. Congestive heart failure.
No clinical suspicion of other sleep disorders CSA. Narcolepsy. PLMD. Parasomnias. Circadian rhythm sleep disorders.
Not for screening asymptomatic populations.Patients who cannot have PSG due to immobility, safety, or critical illness.
Unattended PM may be used to monitor response to non-PAP treatmentsfor sleep apnea (oral appliances, surgery, weight loss).
Unattended PM in patients home is permitted when all guidelines arefollowed.
8/13/2019 OSA Updates
18/64
! Portable Monitoring Task Force of AASMrecommended home studies only after acomprehensive sleep evaluation by a cliniciancertified in sleep medicine and then supervised and
interpreted by person with same level of specialitytraining
8/13/2019 OSA Updates
19/64
! Cost effectiveness analysis have been scarce! PM usually less costly than Laboratory PSG but in some
situations PM can increase cost , delay confirmatorylaboratory testing and encourage treatment of pts with falsepositive results
! One published cost-utility model showed that PSG generatedhigher utility than a portable cardiorespiratory monitory andthe magnitude of the PSG easily justified the added initialexpense
Chervin et al . Ann Intern Med 1999
8/13/2019 OSA Updates
20/64
Pt presents to CSS forevaluation of suspected
OSA
Does pt have high pretestprobability of moderate or
severe OSA
Symptoms or signs ofcomorbid medical
disorders
Symptoms or signs ofcomorbid sleep disorders
In-labPSG
TreatmentOSAdiagnosed?PMSleep study (PM or in lab)
Evaluate for other sleepdisorders, consider in-lab
PSG
OSA diagnosed ?
No
Yes
No
No
No
No
Yes
Yes
Yes
Yes
8/13/2019 OSA Updates
21/64
! Initially was hoped to reduce the average overnightpressure level ! resulting in improved adherence
Subjects Results
Ayas et alSleep 2007
Meta-analysis ofrandomized trials
comparing ACPAPwith fixed pressureCPAP
Mostly men withmoderate to
severe OSAH CPAP-nave No other SRBD
or comorbidities
There were nodifferences in
hours of nightlyuse, despite amean decreasein overnightpressure of 2 cmH20
Smith et al Recent meta-analysis of 30studies
Found a statistically significantdifference of machine usage of 12mins WHICH IS NOT CLINICALLYSIGNIFICANT
8/13/2019 OSA Updates
22/64
! However individual may tolerate APAP>CPAP
! Based on currently available evidence, the AASMsuggests the long term use of autotitrating CPAP inself-adjusting role to treat OSAH as an opt o only
8/13/2019 OSA Updates
23/64
8/13/2019 OSA Updates
24/64
! Medical Treatment for OSA1. End Expiratory Pressure(EPAP) devices2. Oral Pressure Therapy
! Non-medical treatment options for OSA1. Hypoglossal Nerve Stimulation
NONE of these options are more or as efficacious asPAP therapy
8/13/2019 OSA Updates
25/64
FDA cleared in 2008 for treatment of mild, moderate andsevere OSA
Mechanism ofaction
consists of a small valve attached externally to each nostrilwith hypoallergenic adhesive.
valve acts as a one-way resistor, nearly permitting
unobstructed inspiration. During expiration, airflow is directed through small air
channels, increasing resistance. This creates EPAP which is maintained until the start of the
next inspiration. As a result, the device helps pressurizeand stabilize the upper airway during the critical end-expiratory period, when the airway has been found to bemost narrow in the breaths prior to an apnea.
Whereas CPAP provides positive pressure during bothinspiration and expiration, EPAP only creates pressureduring expiration.
8/13/2019 OSA Updates
26/64
8/13/2019 OSA Updates
27/64
Indications Patients (mild, moderate or severe) who have rejected orare non-compliant with prescribed CPAP
Newly diagnosed mild/moderate OSA patients withoutsignificant co-morbidities
CPAP compliant patients looking for alternatives for travel
Contra-indications
Severe breathing disorder (including respiratory muscleweakness, bullous lung disease, bypassed upper airway,pneumothorax, pneumomediastinum, etc)
Severe heart disease (including heart failure) Pathologically low blood pressure An acute upper respiratory (including nasal, sinus or
middle ear) inflammation or infection or perforation of theear drum
Limitations No long term studies Only short term studies No comparison with other forms of alternative therapy
such as oral appliances May cost probably more than CPAP
8/13/2019 OSA Updates
28/64
Evidence Mean AHI reduction in about 50% Berry et al Sleep 2011:
Summary Works in a subset of patients with OSA but no obvious wayto select them
The effectiveness of nasal EPAP is dependent on achieving
sustained expiratory pressure and appears only to bepossible in about 50% of patients
8/13/2019 OSA Updates
29/64
novel treatment for sleep apnea that includes a polymer mouthpiece, tubing,and small console.
Mechanism ofaction
a gentle vacuum that pulls the soft palate and tongue forward Sleep apnea occurs when the upper airway collapses during
sleep ! due to the soft tissues at the back of the mouth and
throat falling back and closing off the passageway for air. macroglossia, may predispose for this occurrence. In addition, excessive tissue at the back of the mouth,
including enlarged tonsils, may also contribute. By bringing these tissues forward with suction, the Winx
system can relieve the obstruction that they may otherwisecause.
The tongue is stabilized, the size of the airway increases, andbreathing improves.
8/13/2019 OSA Updates
30/64
Advantages no bulky mask or restraining headgear without a risk ofpressure sores or skin rashes.
mouthpiece is small and fitted to maximize comfort. The console is quiet and portable no pressurized air with the associated problems of nasal
congestion, leaks, and dryness. preferred to overcome issues related to intimacy andclaustrophobia
Limitations required that you be able to breathe through your nosewithout mouth breathing to use it safely.
If you have underlying lung disease, loose teeth, or advancedperiodontal (gum) disease, you should not use Winx.
One unattractive drawback is that is also sucks saliva (or spit)into a canister that must be emptied in the morning.
Does not work in pts with soft palate surgery
Side effects Swelling of the soft palate Tongue tenderness
8/13/2019 OSA Updates
31/64
The oral pressure therapy system consistsof a bedside console containing a pump, asoft polymer mouthpiece, and a flexibletube connecting the mouthpiece to theconsole.
With the mouthpiece in place, gentleoral vacuum creates a pressuregradient intended to move the softpalate against the tongue to relieveairway obstruction during sleep.
8/13/2019 OSA Updates
32/64
Evidence ATLAST study*: multicenter, prospective, clinical trial was conducted to
determine the safety and effectiveness of the Winx System forthe treatment of OSA
63 pts ( CPAP nave, CPAP rejecters, CPAP users)
Responders :achieved median AHI reduction from 26.2 to 5.7. Median objectively recorded usage per night was 6.0 hours. 76% of participants responded they would use the Winx
System to treat their OSA. Significant reduction of AHI for moderate and severe OSA
Summary DOES NOT WORK FOR EVERYONE If it did not work on first night ,it will not work
*Colrain et al J Sleep Research 2012
8/13/2019 OSA Updates
33/64
! Summary! Newer interventions such as nasal EPAP and oral negative
pressure devices may offer alternatives for some patients.! These devices tend to work better in patients with less severe
disease, and significant residual sleep disordered breathingshould be expected in many patients.
! Long-term data is not available for either one of theseinterventions.
8/13/2019 OSA Updates
34/64
Initially introduced about 15 years ago Due to some technical problems ! no further studies were conducted over
the last 10 yrs Major limitation of previous techniques: induces arousal Not as effacacious as CPAP
Mechanismsof action
implantable HGNS therapy system ! electrical signals aregenerated by an implanted neurostimulator and deliveredto the ipsilateral HGN via an implanted cuff electrode ! stimulates the hypoglossal nerve during sleep opens theupper airway
delivering stimulation immediately prior to and during theinspiratory phase of respiration
Limitations Expensive Invasive
8/13/2019 OSA Updates
35/64
Evidence Prospective single arm interventional trial:* AHI (43 ! 19) ESS ( statistical improvement) Favorable safety, efficacy and complianceSTAR trial multicenter,(randomized, prospective trial) to
demonstrate long-term safety and efficacy Improvement in AHI,ODI,ESS
Summary An alternative option
*Eastwood et al Sleep 2011
8/13/2019 OSA Updates
36/64
8/13/2019 OSA Updates
37/64
8/13/2019 OSA Updates
38/64
! Pts with systolic heart failure and OSA :a) significantly heavierb) snore habituallyc) Have a higher systemic arterial blood pressureOther than these symptoms, the rest of symptoms of OSA andheart failure tend to overlap
8/13/2019 OSA Updates
39/64
! In pts with systolic heart failure, OSA is associated with:1. Increased sympathetic activity2. Reduced left ventricular ejection fraction! Which may be reversed if OSA is treated with CPAP
! In patients with established CAD, OSA is an independentprognostic factor for recurrent cardiovascular disorders andsurvival
! In systolic heart failure, 2 observational studies ! suggests that
OSA contributes to mortality and that CPAP therapy improvessurvival
Kaneko et al NEJM 2003, Mansfield et al Am J Respir Crit Care Med 2004, Egea etal Sleep Medicine 2008Mooe et alAm J Respir Crit Care Med 2001, Peker et al Am J Respir Crit Care Med2000, Hender et al Sleep Med Clin 2007.Hanly et al Chest 1989, Lanfranchi et al Circulation 1999
8/13/2019 OSA Updates
40/64
! Risk factors for OSA in patients with heart failure similar topatients without heart failure
! indications for a PSG are the same as in patients without heartfailure
! In addition; factors that increases suspicion for OSA in heartfailure patients:
1. Nocturnal angina2. Who remain in NYHA Class III and IV or with progressive
systolic or diastolic failure despite optimal medical therapy3. Patients on cardioverter or defibrilator
8/13/2019 OSA Updates
41/64
! In the presence of cardiovascular disease, every attemptshould be made to treat OSA with PAP devices
Optimization of
cardiopulmonaryfunction
To eliminate or improve periodic breathing To decrease right atrial and central venous pressure
! reducing upper airway congestion/edema ! mayresult in increasing upper airway size
Increases lung volumes( FRC) which may improveincrease upper airway size as lung volumes increase
Weight loss Should be advised*
Javaheri et al Int J Cardiol 2006
8/13/2019 OSA Updates
42/64
Avoidance of Alcohol The use increases likelihood of UAocclusion by promoting relaxation ofmuscles of the UABenzodiazepines
Phosphodiesterase-5inhibitors
Its use may worsen OSA In a randomized double blind
placebo controlled study*: 50 mg ofsildenafil significantly increased OSAindex and desaturation in a group ofpatients with OSA
*Roizenblatt et al. Arch Intern Med 2006
8/13/2019 OSA Updates
43/64
PAP devices Treatment of choice Adherence to CPAP is a critical factor
Evidence 4 randomized trials of CPAP therapy in pts with systolicheart failureIn 3 of these studies ; LVEF increased significantly whencompared to control by 10%, 5% and 2%In the 4 th study: CPAP adherence was poorThe increase in LVEF is important because it is a predictorof survival in pts with systolic heart failure
Supplemental
nasal oxygen
For subjects with HF who can not tolerate positive airway
pressure devices- as an alternativeNocturnal O2 improvement in both hypoxemia andperiodic breathing
Kaneko et al NEJM 2003, Mansfield et al Am J Respir Crit Care Med 2004,Egea et al Sleep Medicine 2008, Smith et al Eur Heart J 2007
8/13/2019 OSA Updates
44/64
Upper airwayprocedures
No data in patients with heart failure
Oral appliance Limited data available in heart failure *" in patients with stable CHF who are experiencing
problems with SDB, MAD intervention appears to reducea) the severity of SDBb) sleep apnoea-related symptomsWe speculate the efficacy of these devices in heart failuresimilar to that in general populationPost application repeat sleep study recommended
*Eskafi et al Swedish Dent J Suppl 2004
8/13/2019 OSA Updates
45/64
8/13/2019 OSA Updates
46/64
! Night-time features of SDB include snoring, dyspnea,breathing pauses and sudden awakening with a chokingsensation
! Snoring and shortness of breath are common duringpregnancy usually at 2nd trimester
! The prevalence of snoring during the third trimester rangingfrom 10.4 to 46%
! SDB more common in 3 rd trimester as pregnancy progresses! Pregnant women with apnea symptoms have a higher
likelihood ofi. gestational hypertensive disordersii. gestational diabetesiii. unplanned Caesarian sections
Guilleminault et al Sleep Medicine 2000,Franklin et al Chest 2000, Bourjeily etal Eur Resp J 2010
8/13/2019 OSA Updates
47/64
Physiological changes that potentiate the development of SDB inpregnancy: Reduction in upper airway size( dt weight gain, increased
fluid volume, nasal congestion) Decreased functional residual capacity and residual volume Increasing minute ventilation Supine position and sleep fragmentation
Trakada et al Eur J Obstet Gynaecol Reprod Biol 2003,Izci-Balserak et al Int J Sleep Wakefulness 2008
8/13/2019 OSA Updates
48/64
Physiological changes that prevent the development of SDB inpregnancy: High circulating progesteronei. can protect upper airway from obstructionii. Increase upper airway dilator muscle activity and its
responsiveness to chemical stimuli( CO 2 during sleep)iii. Right-shifted oxyhemoglobin dissociation curve and
increase in heart rate , stroke volume and cardiac outputwith reduction in peripheral vascular resistance ! improvedelivery of oxygen to placenta and fetal tissues
iv. As pregnancy progresses less time spent in supine positionduring sleep
Izci-Balserak et al Int J Sleep Wakefulness 2008,Blyton et al Sleep 2004
8/13/2019 OSA Updates
49/64
8/13/2019 OSA Updates
50/64
! Diagnosis:! Gold standard for diagnostic tests for OSA is the in laboratory
overnight PSG! Limited channel sleep studies have not been validated for use
in pregnant women at this point of time
! The use of a questionnaire for screening OSA would be
helpful! However, the available tools for screening OSA function
poorly in pregnant women
! The Berlin questionnaire:! In primary care : positive predictive value of 0.89! Cohort of pregnant women: sensitivity 35%, specificity 65% 1
1. Netzer et al Ann Intern Med 1999
8/13/2019 OSA Updates
51/64
8/13/2019 OSA Updates
52/64
! Small retrospective and prospective cohort studies havereported an association between OSA and and thedevelopment of pre-eclampsia or gestational HPT
! In these studies, presence of OSA or OSA symptoms was
associated with a twofold increase in pre-eclampsia 1
! A small retrospective study ( n=57) found that women withOSA had a higher rate of preeclampsia than normal weightwomen (19% vs 7%, p = 0.02) 2
1Bourjeily et al Clin Chest Med 2011, 2 Louis et al Am J Obstet Gynecol 2011
8/13/2019 OSA Updates
53/64
! Mechanistic studies demonstrate that OSA-related recurrenthypoxia and re-oxygenation cycles ! increased systemicinflammation , oxidative stress, endothelial dysfunction andincreased oxidative vascular injury 1
! The same pathophysiological mechanisms have beenimplicated in the development of preeclampsia and mayrepresent a common pathway to disease
! Case reports and small cohorts studies to determine whethermaternal OSA increases fetal growth restriction or stillbirth # most observational data suggests it does not 2
1Somers et al Circulation 2008, 2Bourjeily et al Clin Chest Med2011
8/13/2019 OSA Updates
54/64
8/13/2019 OSA Updates
55/64
8/13/2019 OSA Updates
56/64
CPAP In pregnant women: Safe, well-tolerated, with good compliance
Abolish inspiratory flow limitations Reduce mean arterial pressure between wake and sleep by 3
mmHg Reduce severe attacks of dyspnea Improve cardiac output, total peripheral resistance during sleep
and nocturnal oxygenation Improve maternal and fetal outcomes in with pre-eclampsia risk
factorsThese are from case studies or limited studies$ In SDB diagnosed before or at the onset of pregnancy, CPAP MAY
need to be recalibrated around 24 weeks*
Oxygentherapy
Can be considered asi. Combination therapy with CPAPii. In pts who are unable to use CPAP(Pien et al Sleep 2004: although its effectiveness not proven inpregnant population)
Oralappliance
Can be an option but production and fitting sessions can take along time
*Guilleminault et al Sleep Medicine 2007
8/13/2019 OSA Updates
57/64
PregestationalOSA
Should be evaluated by sleep physician, particularly if the ptis :
i. Untreated orii. Has not been evaluated for past 6 mths Can be evaluated for:i. The need for repeat PSGii. Initiation of therapyiii. Reassessment of treatment to ensure it is optimized CPAP is the most effective treatment If unable to tolerate CPAP, even in some moderate-to-severe
cases, a dental appliance for mandibular advancement withtitration can be used
Pts BP and urine protein should also be monitored ( risk ofdeveloping pregnancy related HPT) Suggest early testing for diabetes and repeat glucose
tolerance test at 24 to 28 weeks of gestation (high risk forpre-existing and future diabetes or insulin resistance) 1
1Bourjeily et al Clin Chest Med 2011
8/13/2019 OSA Updates
58/64
Womensuspected ofOSA
Pts with symptoms( excessive daytime sleepiness, witnessedapnea, unexplained hypoxemia) or who are suspected ofOSA should be referred sleep medicine specialist forevaluation
We suggest treatment for all women with mild, moderate orsevere OSA
Post-partumfollow up
Followed up by sleep medicine specialist For reassessment of OSA severity and overall management
and treatment strategy
8/13/2019 OSA Updates
59/64
! Greatest intra-partum risk for women with OSA is anesthesia! Pts with OSA have increased risk ofI. Post-operative hypoxemiaII. HypercapniaIII. Sudden death
! In managing OSA patients in labour and delivery , earlyplacement of regional anesthesia may: 1
i. Prevent the need for general anesthesia if emergencycesarean delivery may be necessary
ii. Obviate the need for parenteral opioids for labor pain
1Bolden et al J clin Anest 2009
8/13/2019 OSA Updates
60/64
8/13/2019 OSA Updates
61/64
! Perioperative hypoxemia should be evaluated for potentialetiologies including life-threatening conditions
! Pts with OSA should be monitored until patient can maintaintheir baseline oxygen saturations while at rest
! Management of sleep apnea related hypoxemia treatment ofunderlying sleep apnea by pts prior determined OSAtreatment( CPAP or oral appliance)
! In absence of an established treatment of OSA , supplementaloxygen could be considered to to avoid hypoxemiaassociated with respiratory events
1Bolden et al J clin Anest 2009
8/13/2019 OSA Updates
62/64
! Pts should be positioned in semi-upright or lateral position
! Analgesic strategy that minimizes need for systemic opioidsshould be used
! If opioids need to be used, single doses rather than standingorders are preferred
! Dose required to induce hypoxemia in patients with OSA isapproximately half the dose required to induce hypoxemia inthose without OSA
1Bolden et al J clin Anest 2009
8/13/2019 OSA Updates
63/64
8/13/2019 OSA Updates
64/64